FreeTheAI

GSK Wins FDA Accelerated Approval for Jemperli in Rectal Cancer

BullishMedium impact
GSKGBX 1,855.00 −0.40%

GSK plc (LSE:GSK) received accelerated approval from the U.S. Food and Drug Administration for Jemperli as the first immunotherapy for adult patients with mismatch repair-deficient or microsatellite instability-high stage II or III locally advanced rectal cancer. The clearance is supported by phase II clinical trial data showing a 68% complete response rate, with no disease recurrences reported in responding patients after more than two years.

The decision opens a new treatment segment in rectal cancer, where the target genetic markers affect roughly 5% to 10% of patients. This regulatory milestone expands the company's oncology footprint beyond its existing indications in gynecologic cancers, providing a first-mover advantage in this patient subset.

Moving forward, international regulatory reviews continue under Project Orbis. Key catalysts to watch include mature trial data required for full regulatory approval, clinical guideline updates, and securing reimbursement coverage from healthcare payers.

Key points

  • The FDA granted accelerated approval for GSK's Jemperli to treat adults with MSI-H/dMMR stage II or III rectal cancer.
  • Jemperli becomes the first approved immunotherapy for this specific rectal cancer patient group.
  • Phase II data showed a 68% complete response rate with no recurrences in responding patients after more than two years.
  • The target biomarker is present in approximately 5% to 10% of rectal cancer cases.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What FDA approval did GSK receive for Jemperli?

The FDA granted accelerated approval for Jemperli to treat adult patients with MSI-H or dMMR stage II or III locally advanced rectal cancer, making it the first approved immunotherapy for this patient group.

What trial results supported Jemperli's approval?

Approval was supported by phase II AZUR-1 trial data showing a 68% complete response rate, with no disease recurrences reported in responding patients past two years.

How large is the addressable patient market for Jemperli in rectal cancer?

The targeted genetic biomarker, MSI-H or dMMR, is present in approximately 5% to 10% of rectal cancer cases.